GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Bioporto AS (OCSE:BIOPOR) » Definitions » Enterprise Value

Bioporto AS (OCSE:BIOPOR) Enterprise Value : kr549.61 Mil (As of Mar. 30, 2025)


View and export this data going back to 1993. Start your Free Trial

What is Bioporto AS Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Bioporto AS's Enterprise Value is kr549.61 Mil. Bioporto AS's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was kr-73.29 Mil. Therefore, Bioporto AS's EV-to-EBIT ratio for today is -7.50.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Bioporto AS's Enterprise Value is kr549.61 Mil. Bioporto AS's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was kr-70.91 Mil. Therefore, Bioporto AS's EV-to-EBITDA ratio for today is -7.75.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Bioporto AS's Enterprise Value is kr549.61 Mil. Bioporto AS's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was kr36.24 Mil. Therefore, Bioporto AS's EV-to-Revenue ratio for today is 15.16.

EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Bioporto AS's Enterprise Value is kr549.61 Mil. Bioporto AS's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was kr-83.58 Mil. Therefore, Bioporto AS's EV-to-FCF ratio for today is -6.58.


Bioporto AS Enterprise Value Historical Data

The historical data trend for Bioporto AS's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioporto AS Enterprise Value Chart

Bioporto AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 979.67 628.83 703.64 734.33 617.49

Bioporto AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 734.33 457.84 821.28 730.02 617.49

Competitive Comparison of Bioporto AS's Enterprise Value

For the Diagnostics & Research subindustry, Bioporto AS's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioporto AS's Enterprise Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Bioporto AS's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Bioporto AS's Enterprise Value falls into.


;
;

Bioporto AS Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Bioporto AS's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as

Bioporto AS's Enterprise Value for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioporto AS  (OCSE:BIOPOR) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Bioporto AS's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=549.609/-73.29
=-7.50

Bioporto AS's current Enterprise Value is kr549.61 Mil.
Bioporto AS's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-73.29 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Bioporto AS's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=549.609/-70.908
=-7.75

Bioporto AS's current Enterprise Value is kr549.61 Mil.
Bioporto AS's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-70.91 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Bioporto AS's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=549.609/36.243
=15.16

Bioporto AS's current Enterprise Value is kr549.61 Mil.
Bioporto AS's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr36.24 Mil.

4. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

Bioporto AS's EV-to-FCF for today is:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=549.609/-83.583
=-6.58

Bioporto AS's current Enterprise Value is kr549.61 Mil.
Bioporto AS's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-83.58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioporto AS Enterprise Value Related Terms

Thank you for viewing the detailed overview of Bioporto AS's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioporto AS Business Description

Traded in Other Exchanges
Address
Tuborg Havnevej 15, Ground Floor, Hellerup, DNK, DK-2900
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America.

Bioporto AS Headlines

No Headlines